1 |
吴国明,钱桂生. 非小细胞肺癌靶向治疗研究进展及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(4): 405-408.
|
2 |
Li Y, Sun C, Tan Y, et al. ITGB1 enhances the radioresistance of human non-small cell lung cancer cells by modulating the DNA damage response and YAP1-induced Epithelial-mesenchymal Transition[J]. Int J Biol Sci, 2021, 17(2): 635-650.
|
3 |
Chen K, Yang F, Shen H, et al. Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer[J]. Cancer Cell, 2023, 41(10): 1749-1762.
|
4 |
Zhou G, Pu Y, Zhao K, et al. Heat shock proteins in non-small-cell lung cancer-functional mechanism[J]. Front Biosci (Landmark Ed), 2023, 28(3): 56.
|
5 |
Puri S, Saltos A, Perez B, et al. Locally advanced, unresectable non-small cell lung cancer[J]. Curr Oncol Rep, 2020, 22(4): 31.
|
6 |
张玉君,石亚飞,戚姝娅,等. 贝伐珠单抗联合化疗治疗非小细胞肺癌患者的疗效及影响因素分析[J]. 临床药物治疗杂志,2023, 21(6): 41-48.
|
7 |
Xu B, Yan M, Ma F, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2021, 22(3): 351-361.
|
8 |
Yuan Y, Liu X, Cai Y, et al. Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis[J]. Syst Rev, 2022, 11(1): 264.
|
9 |
王红阳,张 庆,郭纪全. 呼吸内科疾病诊断标准[M]. 北京:科学技术文献出版社,2009: 69-74.
|
10 |
冯奉仪. 实体瘤新的疗效评价标准(解读1.1版RECIST标准)[C]//中华医学会;中国抗癌协会.中华医学会;中国抗癌协会,2009: 5-8.
|
11 |
Tartarone A, Lerose R, Tartarone M. Management of oligoprogression in non-small cell lung cancer patients[J]. Med Oncol, 2022, 39(5): 56.
|
12 |
Zhao YP, Long Y. Pulmonary toxicity in driver gene positive non-small cell lung cancer therapy[J]. Curr Med Res Opin, 2022, 38(8): 1369-1378.
|
13 |
Coster JN, Groth SS. Surgery for locally advanced and oligometastatic non-small cell lung cancer[J]. Surg Oncol Clin N Am, 2020, 29(4): 543-554.
|
14 |
王文辉,段旭华,李 浩,等. 支气管动脉化疗栓塞联合安罗替尼治疗晚期非小细胞肺癌近期效果观察[J]. 肿瘤研究与临床,2021, 33(12): 908-912.
|
15 |
Lo Russo G, Facchinetti F, Tiseo M, et al. Hyperprogressive disease upon immune checkpoint blockade: Focus on non-small cell lung cancer[J]. Curr Oncol Rep, 2020, 22(5): 41.
|
16 |
张 爽,胡月华,娄桂珍. 同步放化疗治疗Ⅲ期不可切除老年非小细胞肺癌的临床效果及预后因素分析[J]. 实用癌症杂志,2022, 37(5): 769-771, 776.
|
17 |
迟文成,牛泽基,姜家康,等. 六君子汤加味治疗非小细胞肺癌化疗后白细胞减少症的有效性分析[J]. 中医药学报,2022, 50(5): 76-79.
|
18 |
侯 举,孙 吉,欧阳丽辉,等. 劳拉替尼在ALK阳性非小细胞肺癌中的应用[J]. 中南药学,2021, 19(12): 2597-2602.
|
19 |
白雪梅,郭 炫,赵新汉,等. 非小细胞肺癌患者EML4-ALK融合基因突变对个体化靶向治疗预后的影响[J]. 医学临床研究,2021, 38(10): 1483-1489.
|
20 |
陈丽鹃,俞婷婷,单 莉,等. NSCLC患者CYP2D6基因多态性与吉非替尼不良反应相关性研究[J]. 现代肿瘤医学,2021, 29(2): 248-253.
|
21 |
罗教秀,孙世珺,孟凤娇,等. NSCLC患者癌组织Napsin A, TTF-1, ALK, Ki-67表达与临床病理的关系及免疫组化检测意义[J]. 标记免疫分析与临床,2022, 29(12): 2064-2070.
|
22 |
孙 蕾,陈平钰,马爱霞. 劳拉替尼一线治疗间变性淋巴瘤激酶阳性晚期非小细胞肺癌的药物经济学评价[J]. 中国药房,2022, 33(12): 1479-1484.
|
23 |
Cooper O, Bonert VS, Rudnick J, et al. EGFR/ErbB2-targeting lapatinib therapy for aggressive prolactinomas[J]. J Clin Endocrinol Metab, 2021, 106(2): 917-925.
|
24 |
杜重伟,刘 喜,张佳丽. 四君子汤联合鸦胆子油乳注射液对非小细胞肺癌患者免疫功能,肿瘤标志物水平及肺功能的影响[J]. 现代中西医结合杂志,2023, 32(9): 1277-1281.
|
25 |
肖 凌,李和根,徐蔚杰,等. 金复康口服液联合培美曲塞对非小细胞肺癌患者免疫功能,肿瘤标志物及血清VEGF, MMP-9水平的影响[J]. 现代生物医学进展,2021, 21(13): 2503-2507.
|
26 |
Bitay E, Gergely AL, Kántor J, et al. Evaluation of lapatinib-loaded microfibers prepared by centrifugal spinning[J]. Polymers (Basel), 2022, 14(24): 5557.
|
27 |
钟 萍,张 军,凌 华. 非小细胞肺癌患者血清CA125, TIMP-1, SAA水平与临床病理特征和预后的关系[J]. 临床肺科杂志,2022, 27(9): 1411-1415.
|
28 |
刘 华,杨 培,蒋祥德,等. 吉非替尼对晚期非小细胞肺癌患者化疗中癌胚抗原,CYFRA21-1及CA125表达水平的影响[J]. 临床和实验医学杂志,2022, 21(11): 1141-1144.
|
29 |
Huynh TK, Huang CH, Chen JY, et al. miR-221 confers lapatinib resistance by negatively regulating p27kip1 in HER2-positive breast cancer[J]. Cancer Sci, 2021, 112(10): 4234-4245.
|
30 |
何丽媛,王玉栋. ALK激酶域耐药突变的研究进展及未来应对策略[J]. 中国癌症杂志,2022, 32(8): 736-746.
|